RU2001134166A - MELT GRANULATION - Google Patents

MELT GRANULATION Download PDF

Info

Publication number
RU2001134166A
RU2001134166A RU2001134166/14A RU2001134166A RU2001134166A RU 2001134166 A RU2001134166 A RU 2001134166A RU 2001134166/14 A RU2001134166/14 A RU 2001134166/14A RU 2001134166 A RU2001134166 A RU 2001134166A RU 2001134166 A RU2001134166 A RU 2001134166A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
composition according
pharmaceutically acceptable
granular material
obtaining
Prior art date
Application number
RU2001134166/14A
Other languages
Russian (ru)
Inventor
ТЕМЕЛЬОТОВ Дарь ФЕРЧЕЙ (SI)
ТЕМЕЛЬОТОВ Дарья ФЕРЧЕЙ
Юдита ШИРЦА (SI)
Юдита ШИРЦА
Милойка МОХАР (SI)
Милойка Мохар
Мате САЛОБИР (SI)
Матея Салобир
Андрей ГОЛМАЕР (SI)
Андрей ГОЛМАЕР
Марко ОПРЕСНИК (SI)
Марко Опресник
Original Assignee
Лек, Товарна Фармацевтских Ин Кемичних Изделков, Д.Д. (Si)
Лек, Товарна Фармацевтских Ин Кемичних Изделков, Д.Д.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лек, Товарна Фармацевтских Ин Кемичних Изделков, Д.Д. (Si), Лек, Товарна Фармацевтских Ин Кемичних Изделков, Д.Д. filed Critical Лек, Товарна Фармацевтских Ин Кемичних Изделков, Д.Д. (Si)
Publication of RU2001134166A publication Critical patent/RU2001134166A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Deposition Of Substances Of Which Semiconductor Devices Are Composed (AREA)
  • Glanulating (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Claims (14)

1. Фармацевтическая композиция в виде гранулированного материала, отличающаяся тем, что она включает кларитромицин или его производные, покрытые липидным веществом.1. A pharmaceutical composition in the form of a granular material, characterized in that it includes clarithromycin or its derivatives coated with a lipid substance. 2. Фармацевтическая композиция по п.1, отличающаяся тем, что перед гранулированием кларитромицин или его производные смешивают с другими фармацевтически приемлемыми добавками.2. The pharmaceutical composition according to claim 1, characterized in that prior to granulation, clarithromycin or its derivatives are mixed with other pharmaceutically acceptable additives. 3. Фармацевтическая композиция по п.2, отличающаяся тем, что фармацевтически приемлемая добавка представляет собой полимер, нерастворимый в желудке.3. The pharmaceutical composition according to claim 2, characterized in that the pharmaceutically acceptable additive is a polymer insoluble in the stomach. 4. Фармацевтическая композиция по п.3, отличающаяся тем, что полимер, нерастворимый в желудке, представляет собой сополимер метакриловой кислоты и метилметакрилата.4. The pharmaceutical composition according to claim 3, characterized in that the polymer insoluble in the stomach is a copolymer of methacrylic acid and methyl methacrylate. 5. Фармацевтическая композиция по п.1, отличающаяся тем, что липидное вещество представляет собой высший жирный спирт или соответствующую кислоту или их смесь.5. The pharmaceutical composition according to claim 1, characterized in that the lipid substance is a higher fatty alcohol or the corresponding acid or a mixture thereof. 6. Фармацевтическая композиция по п.1, отличающаяся тем, что она, необязательно с добавлением других фармацевтически приемлемых веществ к гранулированному материалу, представлена в виде таблеток или капсул.6. The pharmaceutical composition according to claim 1, characterized in that it, optionally with the addition of other pharmaceutically acceptable substances to the granular material, is presented in the form of tablets or capsules. 7. Фармацевтическая композиция по п.1, отличающаяся тем, что она с добавлением других фармацевтически приемлемых веществ к гранулированному материалу представлена в виде суспензии.7. The pharmaceutical composition according to claim 1, characterized in that it is added in the form of a suspension with the addition of other pharmaceutically acceptable substances to the granular material. 8. Фармацевтическая композиция по п.7, отличающаяся тем, что она не содержит сахар.8. The pharmaceutical composition according to claim 7, characterized in that it does not contain sugar. 9. Фармацевтическая композиция по п.7, отличающаяся тем, что наряду с другими фармацевтически приемлемыми веществами в качестве подслащивающих средств содержит полиолы.9. The pharmaceutical composition according to claim 7, characterized in that, along with other pharmaceutically acceptable substances, contains polyols as sweeteners. 10. Фармацевтическая композиция по любому из предшествующих пунктов, отличающаяся тем, что на нее дополнительно нанесено гастрорезистентное покрытие.10. The pharmaceutical composition according to any one of the preceding paragraphs, characterized in that it is additionally coated with a gastro-resistant coating. 11. Способ получения фармацевтической композиции по любому из пп.1-5, отличающийся тем, что он включает перемешивание до гомогенного состояния смеси гранулированного материала, гранулирование в расплаве и охлаждение.11. A method of obtaining a pharmaceutical composition according to any one of claims 1 to 5, characterized in that it comprises mixing to a homogeneous state a mixture of granular material, melt granulation and cooling. 12. Способ получения фармацевтической композиции по п.11, отличающийся тем, что он дополнительно включает добавление других наполнителей для образования конечного гранулированного материала.12. The method of obtaining the pharmaceutical composition according to claim 11, characterized in that it further includes the addition of other excipients to form the final granular material. 13. Способ получения фармацевтической композиции по п.12, отличающийся тем, что он дополнительно включает нанесение гастрорезистивного покрытия.13. The method of obtaining the pharmaceutical composition according to p. 12, characterized in that it further comprises applying a gastroresistive coating. 14. Фармацевтическая композиция по любому из предшествующих пунктов, которая может применяться для лечения бактериальных инфекций.14. The pharmaceutical composition according to any one of the preceding paragraphs, which can be used to treat bacterial infections.
RU2001134166/14A 1999-05-19 2000-05-18 MELT GRANULATION RU2001134166A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9900119A SI20244A (en) 1999-05-19 1999-05-19 Melt granulation
SIP-9900119 1999-05-19

Publications (1)

Publication Number Publication Date
RU2001134166A true RU2001134166A (en) 2003-08-27

Family

ID=20432471

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001134166/14A RU2001134166A (en) 1999-05-19 2000-05-18 MELT GRANULATION

Country Status (13)

Country Link
EP (1) EP1183013A2 (en)
AU (1) AU4969700A (en)
BG (1) BG106236A (en)
CZ (1) CZ20014133A3 (en)
EE (1) EE200100607A (en)
HR (1) HRP20010932A2 (en)
HU (1) HUP0201233A3 (en)
PL (1) PL351654A1 (en)
RU (1) RU2001134166A (en)
SI (1) SI20244A (en)
SK (1) SK16642001A3 (en)
WO (1) WO2000069415A2 (en)
YU (1) YU82001A (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1267840T3 (en) * 2000-03-28 2009-09-07 Sandoz Ag Granulated particles with masked taste
MXPA03003146A (en) * 2000-10-13 2004-12-06 Advancis Pharmaceuticals Extended release erythromycin derivatives.
AU2003211243B8 (en) 2002-02-21 2008-11-06 Otsuka Pharmaceutical Co., Ltd. Sustained release preparations and process for producing the same
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085342A1 (en) * 1990-06-14 1991-12-15 Milton R. Kaplan Stable aqueous drug suspensions
JP3265680B2 (en) * 1992-03-12 2002-03-11 大正製薬株式会社 Oral pharmaceutical composition
EP0670716B1 (en) * 1992-11-30 2003-03-26 Kv Pharmaceutical Company Tastemasked pharmaceutical materials
IT1312058B1 (en) * 1999-04-09 2002-04-04 Pharmaplus S R L METHOD FOR MICRO-ENCAPSULATION OF MEDICATIONS.

Also Published As

Publication number Publication date
WO2000069415A2 (en) 2000-11-23
SI20244A (en) 2000-12-31
EE200100607A (en) 2003-02-17
SK16642001A3 (en) 2002-05-09
HUP0201233A3 (en) 2003-10-28
YU82001A (en) 2004-07-15
CZ20014133A3 (en) 2002-03-13
BG106236A (en) 2002-08-30
AU4969700A (en) 2000-12-05
WO2000069415A3 (en) 2001-04-26
HRP20010932A2 (en) 2003-04-30
EP1183013A2 (en) 2002-03-06
PL351654A1 (en) 2003-05-19
HUP0201233A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
ES2399810T3 (en) Solid pharmaceutical dosage form comprising a solid dispersion of ritonavir and lopinavir
ES2528359T3 (en) Procedure for the production of an oral medication form with immediate disintegration and release of active substances
CN1160079C (en) Bubbling enteric coated preparations
KR100657779B1 (en) Coated medicament forms with controlled active substance release
US4344968A (en) Pharmaceutical vehicle
JP4828758B2 (en) Injection molding process for (meth) acrylate-copolymers with tertiary ammonium groups
ES2277340T3 (en) FORMULATION OF CONTINUOUS RELEASE CONTAINING THREE DIFFERENT TYPES OF POLYMERS.
FI91482B (en) A process for preparing a sustained release solid dosage form
ES2731881T3 (en) Compositions comprising lipophilic active compounds and method for their preparation
DE69105106T2 (en) FAST SUSPENSABLE PHARMACEUTICAL COMPOSITION.
ES2327034T3 (en) COMPOSITIONS COVERED WITH SUSTAINED RELEASE GEL.
ES2205568T3 (en) LOW TEMPERATURE COATINGS.
EA200000968A1 (en) TWO-PHASE DELIVERY SYSTEM WITH ADJUSTABLE SHIPPING FOR PHARMACEUTICAL MEANS WITH HIGH SOLUBILITY AND METHOD
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
JPS5948415A (en) Long time active matrix tablet
JPH06501685A (en) Solvent-free orally administered pharmaceutical preparation with sustained release of active substance and method for producing the same
JPH08245422A (en) Thermoplastic coating and binder for medical form and peroral or percutaneous medical form containing this
RU2001134166A (en) MELT GRANULATION
JPH0995440A (en) Sustained release preparation and its production
DE69233678D1 (en) AGGLOMERATES WITH HIGH IBUPROFEN CONTENT AND THEIR MANUFACTURING PROCESS
JPH04346930A (en) Stable aspirin enteric tablet
UA80872C2 (en) Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof
WO2012006963A1 (en) Polymer reinforcing agent in controlled release preparation
CN100548270C (en) Improve Pharmaceutical composition of palatability of drugs and preparation method thereof
CN108042506A (en) A kind of enteric plant capsule and its capsule

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20000518